Related Experiment Video

Updated: May 23, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma

S Cedrés1, M A Montero, P Martinez

  • 1Medical Oncology Service/Vall d'Hebron University Hospital, Barcelona, Spain. scedres@vhebron.net

Lung Cancer (Amsterdam, Netherlands)
|March 31, 2012
PubMed
Abstract

Insights

Malignant pleural mesothelioma (MPM) shows frequent activation of the PI3K pathway. Low pS6 protein expression correlates with improved survival, suggesting prognostic value for PI3K pathway markers in MPM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer.
  • Elevated AKT/mTOR signaling is characteristic of MPM.
  • The PI3K pathway is a key regulator of cell growth and survival.

Purpose of the Study:

  • To investigate the expression and phosphorylation of PTEN, PI3K, and downstream signaling proteins in MPM.
  • To determine the prognostic significance of these markers in MPM patients.

Main Methods:

  • Analysis of 30 MPM patient biopsies using immunohistochemistry.
  • Evaluation of clinical data including histology and neutrophil-lymphocyte ratio (NLR).

Main Results:

  • Frequent overexpression of PTEN, mTOR, pAKT, 4E-BP1, eIF-4E, peIF-4E, and FOXO3a was observed.
  • Low pS6 protein expression was significantly associated with longer progression-free survival (PFS) and overall survival (OS).
  • Combined low pS6/p4E-BP1 and high FOXO3a expression predicted significantly better prognosis.

Conclusions:

  • The PI3K pathway and its downstream proteins are frequently activated in MPM.
  • Specific protein expression patterns, particularly pS6, offer prognostic information for MPM.
  • Prospective validation of the PI3K pathway's role in MPM is warranted.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...